Last reviewed · How we verify
LY451395
LY451395 is a small molecule drug developed by Eli Lilly for the treatment of aggression and agitation in Alzheimer's disease patients. It has completed Phase 2 trials but lacks FDA approval. The drug shows promise in managing behavioral symptoms associated with Alzheimer's, though its safety profile and efficacy require further investigation.
At a glance
| Generic name | LY451395 |
|---|---|
| Also known as | mibampator |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |